At the last check on Friday, Travere Therapeutics Inc.’s (NASDAQ:TVTX) stock was up $0.6, moving up 4.20 percent to $14.88. The average number of shares traded per day over the past five days has been 996,541 shares. 3 times new highs have been achieved over the past 5 days, with a $2.20 gain in that time frame. In the last twenty days, the average volume was 959,825, while in the previous 50 days, it was 921,122.
Since last month, TVTX stock retreated -8.60%. Shares of the company fell to $12.57 on 08/23/23, the lowest level in the past month. A 52-week high of $28.38 was reached on 02/17/23 after having rallying from a 52-week low of $12.57. Since the beginning of this year, TVTX’s stock price has dropped by -29.24% or -$5.87, and marked a new high 9 times. However, the stock has declined by -47.57% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
TVTX stock investors should be aware that Travere Therapeutics Inc. (TVTX) stock had its last reported insider trading activity 113 days ago on May 11. Calvin Sandra, the SVP, Chief Accounting Officer of the company, disposed of 122 shares for $16.12 on May 11. It resulted in a $1,967 divestment by the insider. REED ELIZABETH E sold 825 shares at an average price of $16.59 on May 10. The insider now owns 56,611 shares following the transaction. On May 10, Senior Vice President, R&D ROTE WILLIAM E. sold 825 shares at $16.59 apiece. The transaction was valued at $13,687.
Valuation Metrics
The stock’s beta is 0.42. Besides these, the trailing price-to-sales (P/S) ratio of 5.04, the price-to-book (PB) ratio of 9.73.
Financial Health
In the three months ended June 29, Travere Therapeutics Inc.’s quick ratio stood at 3.90, while its current ratio was 4.00, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 3.23, and the total debt-to-equity ratio was 3.23. On the profitability front, the trailing twelve-month gross margin is 95.30% percent. Based on annual data, TVTX earned $204.43 million in gross profit and brought in $212.02 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -65.60%. Return on equity (ROE) for the past 12 months was -273.80%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. TVTX’s revenue rose 9.26% to $56.99 million during the quarter, while net income inched up to $59.7 million. While analysts expected Travere Therapeutics Inc. to report -$1.16 quarterly earnings, the actual figure was -$1.13 per share, beating the consensus estimate by 2.60%. During the quarter, the company generated -$77.01 million in EBITDA. The liabilities of Travere Therapeutics Inc. were 619.94 million at the end of its most recent quarter ended June 29, and its total debt was $406.17 million. The value of shareholders’ equity is $75.01 million.
Technical Picture
This quick technical analysis looks at Travere Therapeutics Inc.’s (TVTX) price momentum. With a historical volatility rate of 56.41%, the RSI 9-day stood at 64.31% on 31 August.
With respect to its five-day moving average, the current Travere Therapeutics Inc. price is up by +16.98% percent or $2.20. At present, TVTX shares trade -2.32% below its 20-day simple moving average and -27.74% percent below its 100-day simple moving average. However, the stock is currently trading approximately -7.67% below its SMA50 and -30.14% below its SMA200.
Stochastic coefficient K was 52.34% and Stochastic coefficient D was 33.66%, while ATR was 0.73. Given the Stochastic reading of 86.31% for the 14-day period, the RSI (14) reading has been calculated as 56.18%. As of today, the MACD Oscillator reading stands at 0.78, while the 14-day reading stands at 0.52.
Analyst Ratings
JP Morgan launched its rating on Travere Therapeutics Inc. (NASDAQ: TVTX) to an Overweight in a note to investors on July 21, 2023. Travere Therapeutics Inc. (TVTX) has been rated Buy by analysts. According to 0 brokerage firms, TVTX is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Travere Therapeutics Inc. stock as buy, with 11 recommending it as overweight.
With a median target price of $25.00, the current consensus forecast for the stock is $17.00 – $41.00. Based on these forecasts, analysts predict Travere Therapeutics Inc. (TVTX) will achieve an average price target of $27.85.
